PL3833662T3 - Inhibitory interakcji białko-białko keap1-nrf2 - Google Patents

Inhibitory interakcji białko-białko keap1-nrf2

Info

Publication number: PL3833662T3
Authority: PL; Poland
Prior art keywords: protein; keap1; nrf2; interaction inhibitors; protein interaction
Prior art date: 2018-08-20

Application number

PL19773579.8T

Other languages

English (en)

Inventor

Wenying Chai

Gavin C. Hirst

Kevin D. Kreutter

David A. Kummer

Kelly J. Mcclure

Rachel T. NISHIMURA

Amy Y. SHIH

Jennifer D. Venable

Hariharan Venkatesan

Jianmei Wei

J. Kent Barbay

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-20

Filing date

2019-08-19

Publication date

2024-05-13

2019-08-19 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2024-05-13 Publication of PL3833662T3 publication Critical patent/PL3833662T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL19773579.8T 2018-08-20 2019-08-19 Inhibitory interakcji białko-białko keap1-nrf2 PL3833662T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201862719978P	2018-08-20	2018-08-20
US201962801433P	2019-02-05	2019-02-05
US201962823450P	2019-03-25	2019-03-25
US201962875737P	2019-07-18	2019-07-18
US201962881639P	2019-08-01	2019-08-01
PCT/US2019/047015 WO2020041169A2 (en)	2018-08-20	2019-08-19	Inhibitors of keap1-nrf2 protein-protein interaction

Publications (1)

Publication Number	Publication Date
PL3833662T3 true PL3833662T3 (pl)	2024-05-13

Family

ID=69523716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL19773579.8T PL3833662T3 (pl)	2018-08-20	2019-08-19	Inhibitory interakcji białko-białko keap1-nrf2

Country Status (29)

Country	Link
US (3)	US10947252B2 (pl)
EP (2)	EP4364804A3 (pl)
JP (2)	JP7212763B2 (pl)
KR (2)	KR102753167B1 (pl)
CN (1)	CN112930347B (pl)
AU (3)	AU2019326368B2 (pl)
BR (1)	BR112021002979A2 (pl)
CL (1)	CL2021000426A1 (pl)
CO (1)	CO2021002670A2 (pl)
CR (1)	CR20210087A (pl)
DK (1)	DK3833662T3 (pl)
EC (1)	ECSP21016032A (pl)
ES (1)	ES2974026T3 (pl)
FI (1)	FI3833662T3 (pl)
HU (1)	HUE065501T2 (pl)
IL (2)	IL280950B2 (pl)
JO (1)	JOP20210030A1 (pl)
MX (1)	MX2021002060A (pl)
MY (1)	MY197921A (pl)
NZ (1)	NZ773129A (pl)
PE (1)	PE20211205A1 (pl)
PH (1)	PH12021500012A1 (pl)
PL (1)	PL3833662T3 (pl)
PT (1)	PT3833662T (pl)
SG (1)	SG11202101613XA (pl)
TW (2)	TWI781342B (pl)
UA (1)	UA126950C2 (pl)
UY (1)	UY38338A (pl)
WO (1)	WO2020041169A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2021002060A (es) *	2018-08-20	2021-07-21	Janssen Pharmaceutica Nv	Inhibidores de la interacción proteína-proteína keap1-nrf2.
BR112021023927A2 (pt) *	2019-05-31	2022-02-08	Ube Industries	Composto, e, composição farmacêutica
US20230107927A1 (en)	2020-02-28	2023-04-06	First Wave Bio, Inc.	Methods of treating iatrogenic autoimmune colitis
JP7681044B2 (ja) *	2020-12-28	2025-05-21	千寿製薬株式会社	Ｎｒｆ２活性化化合物
CN112661655B (zh) *	2020-12-29	2022-02-18	江苏云朴医药新材料科技有限公司	一种1-氨甲基-1-环丙醇类化合物及其合成方法
WO2023210741A1 (ja)	2022-04-28	2023-11-02	第一三共株式会社	ベンゾトリアゾール化合物
KR20250005365A (ko)	2022-04-28	2025-01-09	니혼노야쿠가부시키가이샤	옥심기를 갖는 함질소 복소환 화합물 및 상기 화합물을 함유하는 농원예용 제초제 및 이들의 사용방법
CN115925606B (zh) *	2023-01-05	2023-10-13	宁夏医科大学	一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用
CN116003397B (zh) *	2023-03-24	2023-06-16	凯思凯旭(上海)医药科技有限公司	一种苯并多元环噻唑啉酰胺类化合物及其应用
AU2024251986A1 (en) *	2023-04-03	2025-10-16	Acelink Therapeutics, Inc.	Novel compounds and uses thereof
WO2024262491A1 (ja) *	2023-06-19	2024-12-26	中外製薬株式会社	Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007005879A2 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007008652A2 (en)	2005-07-08	2007-01-18	The University Of North Carolina At Chapel Hill	Methods and compositions directed to dj-1 as regulator of the anti-oxidant transcription factor nrf2
WO2008108825A2 (en)	2006-10-10	2008-09-12	Burnham Institute For Medical Research	Neuroprotective compositions and methods
WO2011156889A1 (en)	2010-06-14	2011-12-22	Trt Pharma Inc.	Novel modulators of nrf2 and uses thereof
JP5988101B2 (ja)	2011-01-21	2016-09-07	国立研究開発法人理化学研究所	酸化ストレスインジケーター発現用核酸構築物とその使用
US9075070B2 (en)	2011-02-09	2015-07-07	Rutgers, The State University Of New Jersey	HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
AU2012222074A1 (en)	2011-02-25	2013-09-12	National Institutes Of Health	Chalcone derivatives as Nrf2 activators
JP2013028575A (ja)	2011-07-29	2013-02-07	Toray Ind Inc	Ｋｅａｐ１タンパク質結合化合物、該Ｋｅａｐ１タンパク質結合化合物とＫｅａｐ１タンパク質の複合体の結晶及びその製造方法
WO2013067036A1 (en)	2011-10-31	2013-05-10	Rutgers, The State University Of New Jersey	Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
SI3444261T1 (sl)	2012-04-27	2021-04-30	Reata Pharmaceuticals, Inc.	2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj
US10054583B2 (en)	2012-10-10	2018-08-21	Temple University Of The Commonwealth System Of Higher Education	Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2
WO2014148455A1 (ja)	2013-03-19	2014-09-25	第一三共株式会社	テルペノイド誘導体
UY35534A (es)	2013-04-24	2014-10-31	Abbvie Inc	Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
WO2014197818A2 (en)	2013-06-07	2014-12-11	The General Hospital Corporation	Small molecule activators of nrf2 pathway
US10980896B2 (en)	2013-10-29	2021-04-20	President And Fellows Of Harvard College	Methods and compositions for inhibiting oxidative stress
AU2014369153B2 (en) *	2013-12-18	2017-09-21	Astex Therapeutics Limited	Nrf2 regulators
EP3107939B1 (en)	2014-02-19	2020-06-17	University of Florida Research Foundation, Inc.	Delivery of nrf2 as therapy for protection against reactive oxygen species
ES2770772T3 (es)	2014-09-10	2020-07-03	Daiichi Sankyo Co Ltd	Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares
ES2570452B1 (es)	2014-10-15	2017-04-19	Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa	Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
US20160120158A1 (en)	2014-11-03	2016-05-05	The Johns Hopkins University	Compositions and methods for the study and treatment of acute kidney injury
WO2016089648A1 (en)	2014-12-01	2016-06-09	Vtv Therapeutics Llc	Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN104825443B (zh)	2015-04-27	2017-10-24	广东省中医院	青蒿烯的抗氧化应用
CA2988338C (en)	2015-06-15	2024-05-14	Glaxosmithkline Intellectual Property Development Limited	Nrf2 regulators
JP2018517732A (ja)	2015-06-15	2018-07-05	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｎｒｆ２レギュレーター
WO2017031223A1 (en)	2015-08-18	2017-02-23	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Activators of nrf2-dependent photoprotection and related uses thereof
WO2017060854A1 (en)	2015-10-06	2017-04-13	Glaxosmithkline Intellectual Property Development Limited	Biaryl pyrazoles as nrf2 regulators
WO2017060855A1 (en)	2015-10-06	2017-04-13	Glaxosmithkline Intellectual Property Development Limited	Arylcyclohexyl pyrazoles as nrf2 regulators
CN105566241B (zh)	2016-01-18	2018-05-25	中国药科大学	1-磺酰胺基-4-芳氧基类化合物、制备方法及其医药用途
US10961271B2 (en)	2016-03-16	2021-03-30	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
CN105753795B (zh) *	2016-04-29	2018-04-13	济南大学	一种具有1,2,3‑三氮唑结构片段的生物碱化合物及其用途
CN109803664A (zh)	2016-06-15	2019-05-24	尚特·德扎尔基西安	用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法
US12227578B2 (en)	2016-11-11	2025-02-18	The Broad Institute, Inc.	Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
WO2018104766A1 (en)	2016-12-06	2018-06-14	Glaxosmithkline Intellectual Property Development Limited	3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
WO2018109641A1 (en)	2016-12-12	2018-06-21	Glaxosmithkline Intellectual Property Development Limited	3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en)	2016-12-12	2018-06-21	Glaxosmithkline Intellectual Property Development Limited	N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es)	2016-12-14	2022-03-23	Glaxosmithkline Ip Dev Ltd	Bisarilamidas como reguladores de NRF2
US11117905B2 (en)	2016-12-14	2021-09-14	Glaxosmithkline Intellectual Property Development Limited	Bisaryl heterocycles as NRF2 activators
JP2020502129A (ja)	2016-12-14	2020-01-23	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｎｒｆ２アクチベーターとしての３−オキソ−１，４−ジアゼピニル化合物
US11059816B2 (en)	2016-12-15	2021-07-13	Glaxosmithkline Intellectual Property Development Limited	Ether linked triazoles as NRF2 activators
AU2017376900A1 (en)	2016-12-15	2019-05-23	Glaxosmithkline Intellectual Property Development Limited	NRF2 compounds
WO2018140876A1 (en)	2017-01-30	2018-08-02	Biogen Ma Inc.	Nrf2 activator
WO2018145109A1 (en) *	2017-02-06	2018-08-09	Massachusetts Institute Of Technology	Methods and products related to glutaminase inhibitors
JP2020097526A (ja)	2017-03-28	2020-06-25	武田薬品工業株式会社	複素環化合物
CN107033100B (zh)	2017-05-24	2019-03-01	济南大学	一种苯并噻唑衍生物、制备方法及其医药用途
CN107236813A (zh)	2017-07-02	2017-10-10	东北林业大学	一种指示Nrf2‑Keap1相互作用的BiFC细胞内检测方法及系统
CN107881195B (zh)	2017-10-26	2021-08-27	深圳市第三人民医院	一种双基因共表达质粒pIRES2-Nrf2-DKK1及其制备方法和应用
RU2020124097A (ru)	2017-12-22	2022-01-24	Медиммьюн Лимитед	НИЗКОМОЛЕКУЛЯРНЫЕ МОДУЛЯТОРЫ ДОМЕНА BTB Keap1
EP3773536A4 (en)	2018-04-06	2022-01-05	The Board of Trustees of the University of Illinois	1,4-SUBSTITUTES OF ISOQUINOLINE USED AS PROTEIN-PROTEIN INTERACTION INHIBITORS BETWEEN KEAP1 / NRF2
US11643407B2 (en)	2018-05-23	2023-05-09	Glaxosmithkline Intellectual Property Development Limited	Indanes as NRF2 activators
CN110724669A (zh)	2018-06-29	2020-01-24	李陶	一种Nrf2基因修饰的脐带间充质干细胞及其制备方法与应用
CN108752245A (zh)	2018-07-16	2018-11-06	宁夏医科大学	萘磺酰胺乙酰胺类化合物及其应用和药物组合物
MX2021002060A (es)	2018-08-20	2021-07-21	Janssen Pharmaceutica Nv	Inhibidores de la interacción proteína-proteína keap1-nrf2.
US20220265635A1 (en)	2018-10-19	2022-08-25	Aclipse One Inc.	Treatment of neurological disease
EP3870578B1 (en)	2018-10-22	2023-08-16	C4x Discovery Limited	Therapeutic compounds
CA3121952C (en)	2018-12-05	2025-05-13	Scohia Pharma, Inc.	MACROCYCLICAL COMPOUND AND ITS USES
US20220088222A1 (en)	2018-12-20	2022-03-24	President And Fellows Of Harvard College	Compositions and methods for the treatment of degenerative ocular diseases
US12122742B2 (en)	2019-01-18	2024-10-22	Rutgers, The State University Of New Jersey	Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction
CN113474349B (zh)	2019-02-15	2024-03-01	葛兰素史密斯克莱知识产权发展有限公司	作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯
CA3135991A1 (en)	2019-04-30	2020-11-05	Sitryx Therapeutics Limited	Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
BR112021023927A2 (pt)	2019-05-31	2022-02-08	Ube Industries	Composto, e, composição farmacêutica
CN110256305B (zh)	2019-07-24	2020-05-26	中国药科大学	一种萘磺酰胺类化合物、制备方法和应用
CN110845435B (zh)	2019-11-28	2021-06-08	中国药科大学	一种过氧化氢响应型Keap1-Nrf2 PPI抑制剂前药、制备方法及其医药用途
CN111362857B (zh)	2020-04-23	2023-02-28	中国药科大学	一类具有吲哚啉骨架的化合物、制备方法及其医药用途
CN112321620B (zh)	2020-11-10	2022-03-29	中国药科大学	一种Keap1-Nrf2 PPI抑制剂前药、制备方法和用途

2019
- 2019-08-19 MX MX2021002060A patent/MX2021002060A/es unknown
- 2019-08-19 KR KR1020237034899A patent/KR102753167B1/ko active Active
- 2019-08-19 AU AU2019326368A patent/AU2019326368B2/en not_active Ceased
- 2019-08-19 TW TW108129422A patent/TWI781342B/zh active
- 2019-08-19 EP EP24151840.6A patent/EP4364804A3/en not_active Withdrawn
- 2019-08-19 JO JOP/2021/0030A patent/JOP20210030A1/ar unknown
- 2019-08-19 PT PT197735798T patent/PT3833662T/pt unknown
- 2019-08-19 UY UY0001038338A patent/UY38338A/es unknown
- 2019-08-19 CN CN201980069221.5A patent/CN112930347B/zh active Active
- 2019-08-19 CR CR20210087A patent/CR20210087A/es unknown
- 2019-08-19 PL PL19773579.8T patent/PL3833662T3/pl unknown
- 2019-08-19 ES ES19773579T patent/ES2974026T3/es active Active
- 2019-08-19 WO PCT/US2019/047015 patent/WO2020041169A2/en not_active Ceased
- 2019-08-19 US US16/544,462 patent/US10947252B2/en active Active
- 2019-08-19 SG SG11202101613XA patent/SG11202101613XA/en unknown
- 2019-08-19 TW TW111142540A patent/TW202309020A/zh unknown
- 2019-08-19 HU HUE19773579A patent/HUE065501T2/hu unknown
- 2019-08-19 JP JP2021509891A patent/JP7212763B2/ja active Active
- 2019-08-19 DK DK19773579.8T patent/DK3833662T3/da active
- 2019-08-19 IL IL280950A patent/IL280950B2/en unknown
- 2019-08-19 MY MYPI2021000864A patent/MY197921A/en unknown
- 2019-08-19 BR BR112021002979-6A patent/BR112021002979A2/pt unknown
- 2019-08-19 KR KR1020217008105A patent/KR102590310B1/ko active Active
- 2019-08-19 UA UAA202101384A patent/UA126950C2/uk unknown
- 2019-08-19 EP EP19773579.8A patent/EP3833662B1/en active Active
- 2019-08-19 IL IL304110A patent/IL304110B2/en unknown
- 2019-08-19 NZ NZ773129A patent/NZ773129A/en unknown
- 2019-08-19 FI FIEP19773579.8T patent/FI3833662T3/fi active
- 2019-08-19 PE PE2021000224A patent/PE20211205A1/es unknown
2020
- 2020-12-18 US US17/127,569 patent/US11897900B2/en active Active
2021
- 2021-02-11 PH PH12021500012A patent/PH12021500012A1/en unknown
- 2021-02-18 CL CL2021000426A patent/CL2021000426A1/es unknown
- 2021-02-26 CO CONC2021/0002670A patent/CO2021002670A2/es unknown
- 2021-03-05 EC ECSENADI202116032A patent/ECSP21016032A/es unknown
- 2021-08-30 US US17/460,775 patent/US11427601B1/en active Active
2022
- 2022-01-25 AU AU2022200478A patent/AU2022200478B2/en not_active Ceased
2023
- 2023-01-13 JP JP2023003696A patent/JP2023038270A/ja active Pending
- 2023-09-29 AU AU2023237198A patent/AU2023237198A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP7212763B2 (ja)	2023-01-25
JP2021535118A (ja)	2021-12-16
FI3833662T3 (fi)	2024-03-01
EP4364804A3 (en)	2024-09-04
UA126950C2 (uk)	2023-02-22
CA3108534A1 (en)	2020-02-27
PT3833662T (pt)	2024-03-18
KR20230146136A (ko)	2023-10-18
MY197921A (en)	2023-07-25
AU2022200478A1 (en)	2022-04-21
MX2021002060A (es)	2021-07-21
US10947252B2 (en)	2021-03-16
CL2021000426A1 (es)	2021-08-20
KR102753167B1 (ko)	2025-01-09
IL280950B2 (en)	2023-12-01
PH12021500012A1 (en)	2021-09-13
KR20210047895A (ko)	2021-04-30
US20200055874A1 (en)	2020-02-20
TW202021594A (zh)	2020-06-16
BR112021002979A2 (pt)	2021-06-08
NZ773129A (en)	2024-11-29
SG11202101613XA (en)	2021-03-30
AU2019326368B2 (en)	2021-11-11
CR20210087A (es)	2021-05-25
CO2021002670A2 (es)	2021-03-08
ECSP21016032A (es)	2021-04-29
ES2974026T3 (es)	2024-06-25
US11427601B1 (en)	2022-08-30
EP4364804A2 (en)	2024-05-08
EP3833662A2 (en)	2021-06-16
KR102590310B1 (ko)	2023-10-17
AU2022200478B2 (en)	2023-07-06
WO2020041169A2 (en)	2020-02-27
AU2023237198A1 (en)	2023-10-19
PE20211205A1 (es)	2021-07-05
EP3833662B1 (en)	2024-01-17
IL280950B1 (en)	2023-08-01
CN112930347A (zh)	2021-06-08
JOP20210030A1 (ar)	2021-02-16
HUE065501T2 (hu)	2024-05-28
TW202309020A (zh)	2023-03-01
US11897900B2 (en)	2024-02-13
US20220315604A1 (en)	2022-10-06
JP2023038270A (ja)	2023-03-16
IL304110B2 (en)	2024-12-01
IL280950A (en)	2021-04-29
UY38338A (es)	2020-02-28
IL304110B1 (en)	2024-08-01
IL304110A (en)	2023-09-01
TWI781342B (zh)	2022-10-21
CN112930347B (zh)	2024-07-23
WO2020041169A3 (en)	2020-04-02
AU2019326368A1 (en)	2021-04-15
DK3833662T3 (da)	2024-02-26

Publication	Publication Date	Title
IL283639A (en)	2021-07-29	Kif18a inhibitors
PL3999506T3 (pl)	2025-05-26	Inhibitory parp1
PL3833662T3 (pl)	2024-05-13	Inhibitory interakcji białko-białko keap1-nrf2
MA54550A (fr)	2022-03-30	Inhibiteurs de kif18a
EP4007752C0 (en)	2025-09-24	Kif18a inhibitors
EP4007753C0 (en)	2025-09-24	Kif18a inhibitors
EP4007756C0 (en)	2025-12-24	KIF18A INHIBITORS
LT3793565T (lt)	2022-02-25	Mcl-1 inhibitoriai
EP3833355A4 (en)	2022-05-11	PRMT5 INHIBITORS
PL3468966T3 (pl)	2021-04-06	Inhibitory interakcji menina-mll
EP3801503A4 (en)	2021-12-08	INHIBITORS OF SARM1
PL3710439T3 (pl)	2023-06-26	Inhibitory kras g12c
PL4051688T3 (pl)	2025-09-22	Inhibitory cd73
MA52813A (fr)	2021-04-14	Inhibiteurs de sarm1
EP3817736A4 (en)	2021-07-28	PIKFYVE INHIBITORS
MA52809A (fr)	2021-04-14	Inhibiteurs de sarm1
EP3773537A4 (en)	2021-05-26	STAT3 INHIBITORS
EP3790871C0 (en)	2024-01-24	FURIN INHIBITORS
EP3804707A4 (en)	2022-03-16	KINASE INHIBITOR
EP3980011A4 (en)	2023-01-18	INHIBITORS OF SARM1
EP3768272A4 (en)	2021-08-11	JAK HEMMER
EP3833669A4 (en)	2022-05-11	PRMT5 INHIBITORS
EP3833668A4 (en)	2022-05-11	PRMT5 INHIBITORS
EP3833664A4 (en)	2022-06-08	SMAD3 INHIBITORS
IL281514A (en)	2021-04-29	O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors